Icure Pharmaceutical Inc
KOSDAQ:175250
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
I
|
Icure Pharmaceutical Inc
KOSDAQ:175250
|
KR |
|
P
|
Protia Inc
KOSDAQ:303360
|
KR |
|
Cementir Holding NV
F:3PC
|
IT |
|
Berkshire Hathaway Inc
MIL:1BRK
|
US |
|
S
|
Sung Kwang Bend Co Ltd
KOSDAQ:014620
|
KR |
|
C
|
Cementir Holding NV
SWB:3PC
|
IT |
|
E
|
Eurofins Scientific SE
XMUN:ESF0
|
LU |
|
I
|
Instone Real Estate Group SE
XMUN:INS
|
DE |
|
Instone Real Estate Group SE
F:INS
|
DE |
|
B
|
Brii Biosciences Ltd
DUS:7SS
|
CN |
Intrinsic Value
Is Icure Pharmaceutical Inc undervalued or overvalued?
See the intrinsic value estimate for Icure Pharmaceutical Inc and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
Fundamental Analysis
What Icure Pharmaceutical Does
Icure Pharmaceutical Inc. engages in the development and manufacture of transdermal drug delivery system. The company is headquartered in Seoul, Seoul. The company went IPO on 2018-07-12. Along with subsidiaries, the Company operates its business through two segments. The Cosmetic segment is involved in the manufacturing and sale of cosmetics including basic cosmetics, mask packs, and patches. In addition, it is also engaged in the production and sale of body, hair care products and fragrances.
- Headquarters
- Korea KR
- IPO date
- Jul 12, 2018
Revenue & Expenses Breakdown
Icure Pharmaceutical Inc
Earnings Waterfall
Icure Pharmaceutical Inc
The intrinsic value for Icure Pharmaceutical Inc (175250) under the Base Case is hidden KRW.
Compared with the current market price of 2 170 KRW, the stock appears hidden.